Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors

Published:2022-11 Issue:6 Volume:8 Page:1696-1702
ISSN:2405-4569
Container-title:European Urology Focus
language:en
Short-container-title:European Urology Focus

Author:

Santoni Matteo,Massari Francesco,Bracarda Sergio,Grande Enrique,Matrana Marc R.,Rizzo Mimma,De Giorgi Ugo,Basso Umberto,Aurilio Gaetano,Incorvaia Lorena,Martignetti Angelo,Molina-Cerrillo Javier,Mollica Veronica,Rizzo Alessandro,Battelli Nicola

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. American Cancer Society. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2020.

2. Artificial neural networks as a way to predict future kidney cancer incidence in the United States;Santoni;Clin Genitourin Cancer,2021

3. The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours;Moch;Eur Urol,2016

4. Impact of clinicopathological features on survival in patients treated with first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors for renal cell carcinoma: a meta-analysis of randomized clinical trials;Rizzo;Eur Urol Focus,2022

5. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis;Santoni;Expert Rev Pharmacoecon Outcomes Res,2022

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma;Expert Review of Pharmacoeconomics & Outcomes Research;2024-09

2. Clinical outcome predictors for metastatic renal cell carcinoma: a retrospective multicenter real-life case series;BMC Cancer;2024-07-05

3. Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results;Clinical Genitourinary Cancer;2024-06

4. Resection of Renal Cell and Prostate Carcinoma Sternum Metastases with Long-Term Follow-Up: A Report of 2 Cases;Case Reports in Oncology;2024-02-23

5. Activating transcription factor 3 is a new biomarker correlation with renal clear cell carcinoma progression;International Journal of Immunopathology and Pharmacology;2024-01